DMN:FRA
Diamyd Medical AB
0,069 €
arrow_upward
+1,02%(+0,00070) 1D
9 նոյ, 22:00:00 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
0,07 €
High
0,07 €
Low
0,07 €
Mkt. cap
148,45 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
Open
0,07 €
High
0,07 €
Low
0,07 €
Mkt. cap
148,45 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
News stories
From web sources and news partners
Yahoo Finance
·
33 րոպե առաջ
The Nasdaq Fell Into Correction Territory Recently. Should You Buy the Dip?
marketscreener.com
·
1 ժամ առաջ
DoubleUGames Launches Tender Offer for Nasdaq-listed DoubleDown
TradingView
·
1 ժամ առաջ
News by CNBC TV18 on TradingView, 2026-11-10 — cnbctv:525bf699f094b:0
WSJ
·
7 ժամ առաջ
U.S. Stocks Climb as Investors Regain Confidence
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB